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Abstract
Background: Some oral antihyperglycemic agents may increase risk of hypoglycemia and thereby reduce patient
quality of life. Our objective was to assess the impact of the severity and frequency of self-reported hypoglycemia on
health-related quality of life (HRQoL) among patients with type 2 diabetes treated with oral antihyperglycemic agents.
Findings: A follow-up survey was conducted in participants with self-reported type 2 diabetes treated with oral
antihyperglycemic agents from the US National Health and Wellness Survey 2007. Data were collected on the
severity and frequency of hypoglycemic episodes in the 6 months prior to the survey, with severity defined as mild
(no interruption of activities), moderate (some interruption of activities), severe (needed assistance of others), or
very severe (needed medical attention). HRQoL was assessed using the EuroQol-5D Questionnaire (EQ-5D) US
weighted summary score (utility) and Worry subscale of the Hypoglycemia Fear Survey (HFS). Of the participants
who completed the survey (N = 1,984), mean age was 58 years, 57% were male, 72% reported an HbA1c <7.0%,
and 50% reported treatment with a sulfonylurea-containing regimen. Hypoglycemic episodes were reported by
63% of patients (46% mild, 37% moderate, 13% severe and 4% very severe). For patients reporting hypoglycemia,
mean utility score was significantly lower (0.78 versus 0.86, p < 0.0001) and mean HFS score was significantly
higher (17.5 versus 6.2, p < 0.0001) compared to patients not reporting hypoglycemia. Differences in mean scores
between those with and without hypoglycemia increased with the level of severity (mild, moderate, severe, very
severe) for utility (0.03, 0.09, 0.18, 0.23) and HFS (6.1, 13.9, 20.1, 25.6), respectively. After adjusting for age, gender,
weight gain, HbA1c, microvascular complications, and selected cardiovascular conditions, the utility decrement was
0.045 (by level of severity: 0.009, 0.055, 0.131, 0.208), and the HFS increase was 9.6 (by severity: 5.3, 12.4, 17.6, 23.2).
HRQoL further decreased with greater frequency of hypoglycemic episodes.
Conclusions: Self-reported hypoglycemia is independently associated with lower HRQoL, and the magnitude of
this reduction increases with both severity and frequency of episodes in patients with type 2 diabetes treated with
oral antihyperglycemic agents.
Background
Lowering blood glucose levels with the use of antihyper-
glycemic agents has been shown to reduce the risk of
diabetic complications [1]. However, achievement of
adequate glycemic control is low for many patients with
type 2 diabetes [2]. One reason for this may be that
long-term maintenance of glycemic control is often a
lower priority than the more immediate risk of hypogly-
cemia [3]. This treatment limitation, induced by some
glucose-lowering medications, may be a major barrier to
successful diabetes care [4,5].
The primary cause of hypoglycemia among patients
with type 2 diabetes is antihyperglycemic medications -
in particular, those which raise insulin levels indepen-
dently of blood glucose, such as sulfonylureas and insu-
lin [6]. Hypoglycemic episodes can occur with differing
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and anxiety) to the very severe (behavioral changes, cog-
nitive impairment, seizures, and coma). The clinical
impact of severe hypoglycemia is substantial in terms of
morbidity, mortality, and quality of life [6]. The well-
being of patients may be affected both directly as a
result of hypoglycemia and indirectly due to fear of
recurring episodes [3]. Furthermore, even mild hypogly-
cemia may be enough to effect clinical management of
diabetes if patient fear compromises their willingness to
take medications as directed [6-8].
Recently, we found that diabetes treatment-related
side effects (i.e., hypoglycemia and weight gain) were
associated with decreased treatment satisfaction and
health-related quality of life (HRQoL) in US patients
treated with oral antihyperglycemic agents [9]. The pur-
pose of the present analysis was to examine the associa-
tion between hypoglycemia and HRQoL based upon the
combination of severity and frequency of hypoglycemic
episodes to better understand the impact of this treat-
ment-related side effect in US patients with type 2 dia-
betes treated with oral antihyperglycemic therapy.
Methods
Survey Sample and Administration
As previously described by Marrett et al. [9], a repre-
sentative sample of the US population was identified
through the 2007 National Health and Wellness Survey
(NHWS), an annual cross-sectional, internet-based sur-
vey of demographics, disease status, healthcare atti-
tudes, behaviors, and outcomes of adults aged 18 and
older. The NHWS sample was stratified by age, gender,
and race/ethnicity to reflect the demographic composi-
tion of the US adult population and verified against
national health statistics. NHWS participants (N =
63,012) were recruited through an internet-based con-
sumer panel, and each completed the survey at 1 of 3
different time points in 2007 - February-March, April
or August.
Based on the results from the original NHWS sam-
ple, 6,349 respondents had self-reported a diagnosis of
type 2 diabetes. These individuals were randomly re-
contacted in November 2007 and asked if they would
be willing to participate in a second internet-based
survey related to their diabetes. The respondents were
also screened to include only those who reported
being treated with one or more oral antihyperglycemic
agents any time during the previous 6 months.
Excluded were those who reported insulin use during
the same time period. Data collection was conducted
until 2,000 follow-up surveys were completed. An
Institutional Review Board (Essex IRB, Lebanon, NJ)
reviewed and approved the protocol and patients pro-
vided informed consent.
Data Collection
Patient demographics and disease characteristics were
collected from the NHWS. These included age, gender,
height, weight, and duration of diabetes. Additional data
collected were history of potential microvascular compli-
cations (macular edema, kidney disease, foot or leg
ulcers, and neuropathic pain,) and selected cardiovascu-
lar conditions (angina, heart attack, stroke, peripheral
vascular disease, and congestive heart failure). At the
second survey patients were asked to provide informa-
tion on recent HbA1c measurements, current use of oral
antihyperglycemic agents, and medication side effects
(weight gain in 12 months and symptoms of hypoglyce-
mia 6 months prior to the second survey).
In order to quantify the frequency and severity of
hypoglycemia, patients were asked to read a list of hypo-
glycemic symptoms and record the frequency of such
symptoms by level of severity. Consistent with the
recommendations of the American Diabetes Association
Workgroup on Hypoglycemia [10], hypoglycemic sever-
ity was categorized as 1) mild (little or no interruption
of activities and no assistance needed to manage symp-
toms); 2) moderate (some interruption of activities and
no assistance needed to manage symptoms); 3) severe
(needed the assistance of others to manage symptoms).
A fourth category of very severe hypoglycemia, was
added to capture episodes that required medical assis-
tance. Patients reported the frequency of hypoglycemia
for each level of hypoglycemic symptom severity (mild,
moderate, severe) during the 6 months preceding the
survey. The frequency data were collected as 1-2 epi-
sodes, 3-6 episodes, >one per month, >one per week, or
daily. Very severe hypoglycemic symptoms were
recorded as the absolute number of episodes experi-
enced over the last 6 months.
Two additional questionnaires were administered dur-
ing the survey. HRQoL was quantified using the non-
disease specific EuroQol-5D Questionnaire (EQ-5D; uti-
lity) [11]. For the purposes of this study, the unweighted
summary scores were transformed to US preference-
weighted index scores (-0.038 to 1.0) [12]. Worry about
hypoglycemia was measured using the Worry subscale
of the Hypoglycemia Fear Survey II (HFS) [7]. The sub-
scale is comprised of 18 questions that measure degree
of patient fear in the past 6 months, and is scaled from
0 to 72 (rated as 0 - 4 [most worry] for each question).
Statistical Analysis
Descriptive statistics summarized patient demographics,
disease characteristics, medication side effects, and
patient reported outcomes. If a participant reported epi-
sodes of hypoglycemia at more than one level of sever-
ity, the individual was classified according to the most
severe level reported (along with the associated
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of mild, moderate, and severe, frequency of hypoglyce-
mia (number of episodes over 6 months) was analyzed
for the following groupings: 1-2 episodes, 3-6 episodes,
and >6 episodes (or >1 episode per month). For very
severe hypoglycemia, frequency was categorized as either
1 episode or ≥2 episodes in the 6 month period. Charac-
teristics of patients with and without reported hypogly-
cemic symptoms were compared using the t-test for
continuous variables and the chi-square test for catego-
rical variables.
Multiple linear regression, adjusting for potential con-
founders, was used to estimate the effect of hypoglyce-
mia on HRQoL and to derive EQ-5D and HFS
decrements relative to no hypoglycemia for 1) any
reported hypoglycemia, 2) level of episode severity, and
3) level of episode frequency and severity. A backwards
selection technique was used to retain variables signifi-
cant at p < 0.1.
Results
Patient Characteristics
Of the 2,008 who participated in the survey, 24 patients
were excluded from further analysis due to incomplete
medication information. For the remaining 1,984
patients, mean age was 58.1y e a r s ,5 7 %w e r em a l e ,a n d
37% reported a weight gain in the previous 12 months
(Table 1). The average duration of diabetes was 7.3
years, 72% had a reported HbA1c of <7.0%, and 50%
reported using an oral treatment regimen that included
a sulfonylurea. Characteristics of patients reporting
hypoglycemic symptoms in the previous 6 months (63%
of patients) were compared to those not reporting
symptoms (37%) (Table 1). In general, patients were
more likely to have reported hypoglycemic symptoms if
they were younger, had more weight gain, had microvas-
cular complications, had selected cardiovascular condi-
tions, or were treated with a sulfonylurea-containing
regimen (all p < 0.01). For those reporting hypoglycemic
Table 1 Patient characteristics by self-reported hypoglycemic symptoms
Characteristic All Patients With Hypoglycemic
Symptoms
Without Hypoglycemic
Symptoms
p-
value
N = 1984 n = 1248 (63%) n = 736 (37%)
Female (%) 43 47 37 <.0001
§
Male (%) 57 53 63
Age, years 58.1 ± 11.1 56.8 ± 11.2 60.4 ± 10.4 <.0001
‡
Body mass index, kg/m
2 34.5 ± 8.2 34.8 ± 8.4 34.0 ± 7.9 0.0229
‡
Duration of diabetes, years 7.3 ± 6.4* 7.2 ± 6.2 7.5 ± 6.6 0.2737
‡
HbA1c <7%
† (%) 72.2 71.4 73.6 0.3667
§
Any weight gain (%) 36.9 41.5 29.1 <.0001
§
Amount of weight gain
<10 lbs (%) 27.9 25.9 32.7
10-20 lbs (%) 47.5 48.7 44.9 <.0001
¶
21-30 lbs (%) 12.3 12.6 11.7
>30 lbs (%) 12.3 12.9 10.8
Microvascular (%) 22.5 25.8 16.9 <.0001
§
Macular edema (%) 4.0 4.8 2.6 0.0143
§
Kidney disease (%) 2.5 2.9 1.8 0.1210
§
Foot or leg ulcer (%) 3.6 4.2 2.6 0.0663
§
Neuropathic pain (%) 17.3 20.4 12.1 <.0001
§
Selected cardiovascular conditions (%) 19.5 21.6 15.9 0.0018
§
Angina (%) 8.5 9.9 6.3 0.0054
§
Heart attack (%) 8.0 8.2 7.7 0.7342
§
Stroke (%) 4.3 4.7 3.5 0.2042
§
Peripheral vascular disease (%) 0.96 1.0 0.82 0.6169
§
Congestive heart failure (%) 4.3 4.7 3.7 0.2983
§
Current antihyperglycemic agents regimen
Treatment regimen including a sulfonylurea (%) 50 55 42 <.0001
¶
All other treatment regimens (%) 50 45 58
Data are presented as frequency and mean ± standard deviation.
*median 6 yrs.; 25th percentile 3 yrs.; 75th percentile 10 yrs.
†n = 1439
Based on
‡ t-test,
§ chi-square, or
¶ Wald test of joint significance.
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reported symptoms, while for those not reporting symp-
toms, men were more likely not to report symptoms
than women (p < 0.001) (Table 1).
Reported Hypoglycemic Symptoms
Of patients reporting hypoglycemic symptoms and
severity level (n = 1183), 45.6% experienced mild symp-
toms, 37.4% moderate, 13.2% severe, and 3.8% very
severe symptoms (Table 2). For those reporting the fre-
quency of hypoglycemic episodes in the 6-month period
prior to the survey (n = 1172), 60% of patients reported
having 1-2 episodes of hypoglycemia, 22% had 3-6 epi-
sodes, and 14% had >6 episodes (or >1 episode per
month). For very severe hypoglycemic symptoms, 2.1%
experienced one episode and 1.4% ≥2 episodes over the
6 month period. The breakdown of frequency groupings
by levels of severity is in Table 2.
Association between Hypoglycemic Symptoms and Utility
Decrements/EuroQol-5D
For patients reporting any hypoglycemic symptoms, the
unadjusted mean utility score was significantly lower
(0.78 versus 0.86, respectively; p < .0001) compared to
patients with no symptoms (Table 3). In addition,
between-group differences in unadjusted mean utility
score for those with and without hypoglycemic symp-
toms increased with symptom severity (Table 3). After
adjusting for age, gender, weight gain, proportion with
HbA1c <7% (any hypoglycemia model only), microvascu-
lar complications, and selected macrovascular condi-
tions, the adjusted mean utility score (reference = no
hypoglycemia) was 0.045 lower (p < 0.001) for those
reporting any hypoglycemic symptoms and by symptom
severity: mild 0.009, moderate 0.055, severe 0.131, and
very severe 0.208 (Table 3). Utility scores further
decreased within each severity level when frequency of
hypoglycemic episodes was taken into account (Figure
1). Duration of diabetes and current medication regimen
( t h o s ew i t has u l f o n y l u r e av s .t h o s ew i t h o u t )w e r en o t
significant factors (p > 0.1) and were excluded during
the model backward selection.
Association between Hypoglycemic Symptoms and
Quality of Life Reductions/HFS
The unadjusted mean HFS score was significantly higher
(17.5 versus 6.2, respectively; p < 0.001) for patients
reporting hypoglycemic symptoms compared to patients
with no symptoms, and between-group differences
increased with symptom severity (Table 4). After adjust-
ing for age, gender, weight gain, microvascular compli-
cations and selected cardiovascular conditions, the HFS
score (reference = no hypoglycemia) was 9.6 points
higher (p < 0.001) for patients reporting any hypoglyce-
mic symptoms, and the between-group difference
increased with symptom severity (Table 4). HFS scores
further increased within each severity level when fre-
quency of hypoglycemic episodes was taken into
account (Figure 2). Duration of diabetes, proportion
with HbA1c <7%, and current medication regimen were
not significant factors (p > 0.1) and were excluded dur-
ing the model backward selection.
Discussion
In this study of US patients with type 2 diabetes treated
with oral antihyperglycemic agents, symptoms of hypo-
glycemia were common and reported by nearly 63% of
patients, 17% of whom reported severe or very severe
events. The proportion of patients reporting hypoglyce-
mic symptoms in the present study is higher than that
(16 to 39%) previously reported by US and European
patients treated with oral antihyperglycemic agents
[13-16]. The present results suggest that hypoglycemia
may be more common for patients treated with oral
antihyperglycemic agents than previously reported. It is
difficult, however, to compare the incidence of hypogly-
cemia across studies due to different study designs and
populations, medication regimens, and definitions of
hypoglycemia [14-16].
Hypoglycemia was shown to be independently asso-
ciated with lower patient utility, and that disutility
increases with severity of hypoglycemic episode in the
present study. Similar, although non-significant, results
were obtained in a study of Swedish type 2 diabetic
patients treated with oral antihyperglycemic agents and/
or insulin. Based on the EQ-5D, Lundkvist et. al. [3]
reported a utility decrement of 0.047 (p = 0.120) for
patients experiencing any hypoglycemia in the preceding
month, after adjusting for gender, insulin use, and hypo-
glycemia group (symptomatic, mild or severe). The
Table 2 Severity and frequency of self-reported
hypoglycemic symptoms
Severity level Number of self-reported symptoms (N = 1172)
Category* Frequency %
Mild 1 to 2 27.8
3 to 6 12.1
>1/month 5.9
Moderate 1 to 2 24.0
3 to 6 7.4
>1/month 6.2
Severe 1 to 2 8.2
3 to 6 2.8
>1/month 2.1
Very Severe 1 2.1
≥2 1.4
* Based on number of hypoglycemic episodes in previous 6 months.
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and patient disutility in the present analysis was similar
to that reported for French patients with type 2 diabetes
treated with a combination of metformin and sulfony-
lurea. For patients reporting hypoglycemic episodes in
the previous 6 months, the EQ-5D decreased by 0.07 for
mild, 0.08 for moderate and 0.27 for severe/very severe
hypoglycemic episodes, after adjusting for patient and
disease characteristics [15].
Reported hypoglycemic symptoms were also demon-
strated to be significantly associated with fear of hypo-
glycemia (as assessed by the HFS Worry scores), and
that the magnitude of fear increases with severity of epi-
sode in the present study. Vexiau et al. [15] reported
HFS scores that increased by 7.9 for any hypoglycemia,
and by 5.8 for mild episodes, 11.1 for moderate, and
13.4 for severe episodes after adjusting for patient and
disease characteristics. Although these decrements are
smaller overall than those found in the present study,
the positive linear association between severity of hypo-
glycemic episode and greater fear is consistent.
In general, patients who experience severe and/or fre-
quent hypoglycemic episodes report lower general
health and greater fear of hypoglycemic events com-
pared with patients who do not experience hypoglyce-
mia. The need to avoid hypoglycemia and the long-term
consequences of hyperglycemia remain a challenge in
disease management. Patients may prioritize the
immediate risk of hypoglycemia over the possibility of
future health problems [17]. It has been suggested that
patients may intentionally take less diabetes medication
(i.e., reduce treatment compliance) or over-eat to
increase their blood glucose level in order to avoid
hypoglycemia [3,17,18]. Hypoglycemic episodes not only
Table 3 Mean EQ-5D scores and utility decrements* for presence of hypoglycemic symptoms and episode severity
Hypoglycemic Episode Level n Mean EQ-5D Score Unadjusted Decrement Adjusted Decrement
†
No Hypoglycemia 736 0.86 0 0
Any Hypoglycemia 1248 0.78 -0.08 -0.05
‡
Mild 540 0.83 -0.03 -0.01
Moderate 442 0.77 -0.09 -0.06
‡
Severe 156 0.68 -0.18 -0.13
‡
Very Severe 45 0.63 -0.23 -0.21
‡
* Reference group: no hypoglycemia
† Adjusted for age, gender, weight gain, proportion with HbA1c <7% (any hypoglycemia model only), microvascular complications and selected cardiovascular
conditions.
‡ Parameter estimates p < 0.0001.
Figure 1 Adjusted EQ-5D decrements by severity and frequency of hypoglycemic symptoms (based on the number of hypoglycemic
episodes in previous 6 months) relative to the reference group with no hypoglycemia.
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patients, but the fear resulting from the side effect may
negatively impact long-term diabetes outcomes if accep-
table glucose levels are not maintained.
In addition to quantifying the impact of hypoglycemia
on patients’ HRQoL, these data are important for deter-
mining the value of treatment. Health-related utility
from the EQ-5D is a generic measure of health status
and is often used to determine the relative cost-effec-
tiveness of a given drug or drug regimen [18]. Although
these analyses are frequently used to estimate treatment
outcomes for patients with type 2 diabetes, few utility
measures are available for medication-related side effects
that may be important to patients [19]. Although disuti-
lity was associated with both the severity and frequency
of hypoglycemic symptoms, further research is needed
to understand how fear of hypoglycemia impacts health-
related utility in patients with type 2 diabetes treated
with oral antihyperglycemic agents.
The following limitations need to be considered in the
interpretation of the present results. The NHWS sam-
pling frame was stratified by age, gender, and race/eth-
nicity. Some degree of selection bias in terms of literacy
level and socioeconomic status, however, may be pre-
sent. Individuals without access to internet technology
may be under-represented, resulting in a study popula-
tion with a somewhat higher education and/or income
than the national average. Better methods are needed
for the classification of hypoglycemia, particularly mild
events. Characterization of mild symptoms can be diffi-
cult because they may occur due to reasons other than
low blood sugar (e.g. headache, hunger, sweating) [20],
which may result in over-estimation of hypoglycemia.
This may, in part, explain the high overall prevalence of
Table 4 Mean HFS scores and quality of life decrements* for presence of hypoglycemic symptoms and episode
severity
Hypoglycemic Episode Level n Mean HFS Score Unadjusted Decrement Adjusted Decrement
†
No Hypoglycemia 736 6.2 0 0
Any Hypoglycemia 1248 17.5 11.3 9.6
‡
Mild 540 12.3 6.1 5.3
‡
Moderate 442 20.1 13.9 12.4
‡
Severe 156 26.3 20.1 17.6
‡
Very Severe 45 31.8 25.6 23.2
‡
* Reference group: no hypoglycemia
† Adjusted for age, gender, weight gain, microvascular complications and selected macrovascular conditions.
‡ Parameter estimates p < 0.0001.
Figure 2 Adjusted HFS decrements by severity and frequency of hypoglycemic symptoms (based on the number of hypoglycemic
episodes in previous 6 months) relative to the reference group with no hypoglycemia.
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glycemia is also subject to difficulties of recall. In the
present study, patients were asked to report hypoglyce-
mic symptoms that occurred in the previous 6 months.
The gold standard for characterization of hypoglycemia
requires measurement of blood glucose and documenta-
tion of hypoglycemia in the presence of typical symp-
toms, which may not always be possible for patients
[18]. Health-related utility can be affected by many fac-
tors. Although the estimates were adjusted for patient
characteristics and comorbid disease, there may be
other unmeasured factors that influence utility that are
unaccounted for. In addition, because of the cross-sec-
tional design of this study, temporal relationships cannot
be determined (e.g., the influence of hypoglycemia on
subsequent health status, or the influence of lower
health status on reporting symptoms of hypoglycemia).
Current treatment regimen was comprised of monother-
apy, dual therapy, and triple therapy with oral antihyper-
glycemic agents, which may have confounded individual
effect of each agent. Previous medication use, rather
than current medications, may also have affected
patients’ perceptions regarding hypoglycemia.
Conclusions
In this survey of US patients with type 2 diabetes who
were treated with oral antihyperglycemic agents, nearly
two-thirds reported experiencing hypoglycemic symp-
toms. The self-reported hypoglycemic symptoms were
independently associated with reduced HRQoL, and the
magnitude of this reduction increased with both the
severity and frequency of the symptoms. Thus, further
research is required to determine if therapeutic agents
that have a lower risk of hypoglycemia positively influ-
ence both patient quality of life and long-term outcomes.
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